HMGB1, an endogenous ligand of TLR4, can drive the pathogenesis of inflammatory and angiogenic diseases and immune regulation, such as CNV, ischemia-reperfusion injury and hemorrhagic shock, though HMGB1/TLR4 signaling pathway [45,46,47,48]. Here, TLR4 is linked to ischemia.